RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) authorized the emergency use of an experimental drug - Sotrovimab - for treating patients with Covid-19, .
The drug was authorized for use in patients with mild to moderate symptoms and at risk of developing into a severe condition: for example, individuals who are 65 years of age and older or who have certain medical conditions. It is contraindicated for hospitalized patients who require ventilatory support.
The monoclonal antibody therapy manufactured by Glaxo Smith Kline LLC (GSK) was given emergency approval on May 26 by the U.S. FDA for the same . . .